Vaccination recommendations for the elderly
Keywords:
Vaccination, immunization, elderly, agedAbstract
This review article aims to update vaccination recommendations for the elderly. The increase in longevity and the greater occurrence and severity of complications associated with vaccine-preventable diseases in the elderly population demands the implementation of public health programs and policies aimed at this age group.
References
Department of economic and social affairs world social report 2023: Leaving no one behind in an ageing world-United Nations.
World Health Organization (WHO). Immunization Agenda 2030: a global strategy to leave no one behind; 2022 [Acesso em: 2022 Nov 18].
Bloom D, Fan V, Sevilla J. The broad socioeconomic benefits of vaccination. Sci Transl Med. 2018;10 (441): eaaj234. DOI:10.1126/ scitranslmed.aaj2345.
Peck M, Gacic-Dobo M, Diallo M, Nedelec Y, Sodha S, Wallace A. Global routine vaccination coverage, 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(42):937-42. DOI:10.15585/mmwr.mm6842a1.
Patel M, Dumolard L, Nedelec Y, Sodha S, Steulet C, Gacic-Dobo M, Kretsinger K, et al. Progress toward regional measles elimination — worldwide, 2000-2018. Morb Mortal Wkly Rep. 2019; 68(48):1105-11. DOI:10.15585/mmwr. mm6848a1.
Gavazzi G, Krause K. Ageing and infection. Lancet. 2002; 2:659-66. https://doi. org/10.1016/S1473-3099(02)00437-1).
A review of factors influencing vaccination policies and programs for older adults globally. Eiden AL, Barrattb J, Nyakua MK. Human Vaccines & Immunotherapeutics 2023; Vol. 19, NO. 1, 2157164 https://doi.org/10.1080/21645515.2022.2157164.
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018; 391(10127):1285-300.
Araújo R, Watanabe SF, Boiron L, Pereira ACPR, Asano E. Economic impact of influenza infection in Brazil: analysis from the health systems and society perspective in 2019. J Bras Econ Saúde 2021; 13(3):300-9. DOI: 10.21115/JBES.v13.n3.p300-9.
Webster RG, Bean WJ, Jr. Genetics of influenza virus. Annu Rev Genet. 1978; 12:415-31.
Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, et al. Triple reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med. 2009; 360(25):2616-25.
Silva PCR. Tese de Doutorado Biologia Celular e Molecular: Dinâmica Molecular dos vírus Influenza A (H1N1) Pandêmico em cinco anos de circulação no Brasil.
Christman MC, Kedwaii A, Xu J, Donis RO, Lu G. Pandemic (H1N1) 2009 virus revisited: An evolutionary retrospective. Infect Genet Evol. 2011; 11(5):803-11.
Medina RA, Garcia-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol. 2011; 9(8):590-603.
Ministério da Saúde. Informe Técnico Operacional. Vacinação contra a Influenza; Brasília 2023.
Barros et al. Patterns of influenza B circulation in Brazil and its relevance to seasonal vaccine composition. Braz J Infect Dis 20 (1); 2016. doi.org/10.1016/j.bjid.2015.09.009
Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Rajaram S, Boikos C, Gelone DK, and Gandhi A. Ther Adv Vaccines Immunother. 2020; 8: 2515135520908121. Published online 2020 Feb 22. DOI: 10.1177/2515135520908121.
Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta- analysis. Vaccine 2021; 39 Suppl 1:A24. Supported by Sanofi Pasteur.
https://www.cdc.gov/flu/prevent/qa_fluzone.htm
https://www.uptodate.com/contents/seasonal-influenza-vaccination-in-adults?source= mostViewed_widget
Perdrizet J, et al. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil Infants. Human Vaccines & Immunotherapeutics. 2020; 17(4): 1162-1172.
Simell B, et al. Pneumococcal Carriage Group. The fundamental link between pneumococcal carriage and disease. Expert Review of Vaccines 2012; 11: 841-855.
Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 16(6):335-367, 2018.
Almeida S, et al. Low prevalence of Pneumococcal carriage and high serotype and genotype diversity among adults over 60 years of age living in Portugal. PLOS ONE. 9(3): e90974, 2014.
Arguedas A, et al. Upper Respiratory Tract Colonization with Streptococcus pneumoniae in adults. Expert Review of Vaccines. 19(4):353-366, 2020.
Centers for Disease Control and Prevention (CDC). 2020. National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases. Pneumococcal Disease. Disponível em: https://www.cdc.gov/pneumococcal/clinicians/streptococcus-pneumoniae.html. Acesso em: 01 Jun 2021.
Krone CL, et al. Immunosenescence and pneumococcal disease: an imbalance in host pathogen inteactions. Lancet Respir Med 2014; 2:141-153.
Austrian R & Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 1964; 60:759-76.
Centers for Disease Control and Prevention (CDC). 2005. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Motal Wkly Rep. 54: 893 – 897, 2005.
Centers for Disease Control and Prevention (CDC). 2020. Biggest Threats and Data CDC’s Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report). DOI: https://www.cdc.gov/drugresistance/biggest-threats.html Acesso em: 23.07.2021.
Paton JC, Trappetti C. Streptococcus pneumoniae capsular polysaccharide. Microbiol Spectrum 2018; 7(2): GPP3 - 0019.
Brueggemann AB, et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. v. 3, n. 11, p. 11- 168. Nov. 2007
https://sbim.org.br/calendarios-de-vacinacao
https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html
https://www.cdc.gov/mmwr/volumes/72/rr/rr7203a1.htm#T2_down
Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341.
Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.
United States Centers for Disease Control and Prevention. Shingles Surveillance. DOI: http://www.cdc.gov/shingles/surveillance.html (Acesso em: 01 Jul 2016).
Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481.
Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008; 115:S3.
Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157:1217.
Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342:341.
UpToDate: herpes zoster Mary A Albrecht, MD; Myron J Levin, MD. This topic last updated: Feb 24, 2022.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087.
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016; 375:1019.
Boutry C, Hastie A, Diez-Domingo J, et al. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clin Infect Dis 2022; 74:1459.
Schwarz TF, Volpe S, Catteau G, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 2018; 14:1370.
Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study. Clin. Infect. Dis. 2021; 73, 949-956.
Izurieta HS, Wu X, Forshee R, Lu Y, Sung H-M, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, et al. Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure. Clin. Infect. Dis. 2021; 73, 941-948.
Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:80.
https://www.uptodate.com/contents/vaccination-for-the-prevention-of-shingles-herpes-zoster.
Colindres R, Wascotte V, Brecx A, et al. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother 2020; 16:2628.
Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep 2019; 68:91.
Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103.
https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html
https://sbim.org.br/images/calendarios/calend-sbim-idoso.pdf
COVID-19 Cumulative Infection Collaborators Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet. 2022;399(10344):2351. Epub 2022 Apr 8.
https://www.cdc.gov/vaccines/vpd/rsv/public/older-adults.html
Papi A, Ison MG, Langley JM, et al.; AReSVi-006 Study Group. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023; 388:595-608. DOI: https://www.nejm.org/doi/10.1056/NEJMoa2209604. PMID:36791160.
Walsh EE, Pérez Marc G, Zareba AM, et al.; RENOIR Clinical Trial Group. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388:1465–77. DOI: https://www.nejm.org/doi/10.1056/NEJMoa2213836. PMID:37018468.
Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:793–801. DOI: http://dx.doi.org/10.15585/mmwr.mm7229a4.
